Q-omics provides the consensus-scored MYD88 profile across patient tissues and cancer cell-line models. MYD88 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MYD88 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MYD88 protein abundance shows 23,901 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight HNSC, and KIRC as cancer lineages where MYD88 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYD88 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYD88 survival associations across molecular data types. MYD88 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYD88 RNA expression–survival associations across cancer types. High MYD88 expression shows unfavorable associations in LGG and ACC, but favorable associations in HNSC, KIRC, SCLC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MYD88 RNA expression.
This table summarizes MYD88 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MYD88. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYD88 shows lower tumor expression in KICH and LUSC and higher tumor expression in KIRC, STAD, UCEC and KIRP. The KIRC box plot shows higher MYD88 RNA expression in tumor versus normal tissue (log2 FC = +0.828, t-test p < 0.001).
This table shows molecular features associated with MYD88 in patient tissues and cancer cell lines. In patient samples, MYD88 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYD88 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
